Moreover, although METTL3 targets Runx2, VEGF and different signaling pathways to promote osteogenic differentiation, it remains controversial whether METTL3 is a potential therapeutic target for osteoporosis, as METTL3 also activates osteoclasts and then increases bone resorption. Here, RUNX2 is linked to osteoporosis.